Predictors of relapse and overall survival in Philadelphia chromosome–positive acute lymphoblastic leukemia after transplantation Derek L. Stirewalt,

Slides:

Advertisements

Similar presentations

Extramedullary Relapse of Acute Leukemia after Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical.

Advertisements

Implications and Management of Central Nervous System Involvement before Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia

Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Prevention of Graft-versus-Host Disease following Hematopoietic Cell Transplantation.

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

Olga Sala Torra, Megan Othus, David W

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation Anne Mette Mørup, Brian.

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis Armin Rashidi,

The Level of Minimal Residual Disease in the Bone Marrow of Patients with Multiple Myeloma before High-Dose Therapy and Autologous Blood Stem Cell Transplantation.

Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous.

First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation

Jacob M. Rowe Biology of Blood and Marrow Transplantation

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival Sangeeta R. Hingorani, Kristy Seidel,

Quantifying the Survival Benefit for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Acute Myelogenous Leukemia Paul M. Armistead, Marcos.

Study Design of an Expanded Access Protocol of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients Years of Age with Secondary Acute.

Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia Vivian.

Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for the Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic.

Impact of Pretransplantation Risk Factors on Post Transplantation Outcome of Patients with Acute Myeloid Leukemia in Remission after Haploidentical Hematopoietic.

Posttransplant Thrombopoiesis Predicts Survival in Patients Undergoing Autologous Hematopoietic Progenitor Cell Transplantation Mary J. Ninan, Christopher.

Favorable Outcome for Infant Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation David A. Jacobsohn, Brad Hewlett, Elaine Morgan,

Incidence Rate of Fluoroquinolone-Resistant Gram-Negative Rod Bacteremia among Allogeneic Hematopoietic Cell Transplantation Patients during an Era of.

Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological.

A Phase I/II Study of Chemotherapy Followed by Donor Lymphocyte Infusion plus Interleukin-2 for Relapsed Acute Leukemia after Allogeneic Hematopoietic.

High Rate of Long Term Complete Remission for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapse after Allogeneic Stem Cell Transplantation.

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:

Paul Szabolcs, Donna Niedzwiecki

Practical Radiation Oncology

Biology of Blood and Marrow Transplantation

Unrelated Cord Blood Transplantation in Adult and Pediatric Acute Lymphoblastic Leukemia: Effect of Minimal Residual Disease on Relapse and Survival

Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome Iskra Pusic,

Marrow Fibrosis as a Risk Factor for Posttransplantation Outcome in Patients with Advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia with Multilineage.

Patients with Philadelphia-Positive Leukemia with BCR-ABL Kinase Mutations before Allogeneic Transplantation Predominantly Relapse with the Same Mutation

Hematopoietic Cell Transplantation as Curative Therapy for Idiopathic Myelofibrosis, Advanced Polycythemia Vera, and Essential Thrombocythemia Daniella.

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia George L. Chen, Hong Liu,

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation

Reduced-Intensity Conditioning followed by Peripheral Blood Stem Cell Transplantation for Adult Patients with High-Risk Acute Lymphoblastic Leukemia

Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic.

Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell– Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous.

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

Immunoglobulin and T Cell Receptor Gene High-Throughput Sequencing Quantifies Minimal Residual Disease in Acute Lymphoblastic Leukemia and Predicts Post-

Haploidentical/Mismatched Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for T Cell Acute Lymphoblastic Leukemia Yu Wang,

Allogeneic Bone Marrow Transplantation in First Remission for Children with Ultra-high- risk Features of Acute Lymphoblastic Leukemia: A Children’s Oncology.

Improved Outcomes after Autologous Bone Marrow Transplantation for Children with Relapsed or Refractory Hodgkin Lymphoma: Twenty Years Experience at a.

Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS Aaron T. Gerds, Ted A. Gooley,

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Abnormalities of the Short Arm of Chromosome 17 Jinichi.

HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category Ann Woolfrey, Stephanie J.

Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents Moreno Festuccia, Kelsey Baker, Theodore.

Blood and Marrow Transplant Handbook

IFN-α Is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation:

Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome Bart L. Scott, Barry Storer,

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

4-Hydroperoxycyclophosphamide–purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia David A. Rizzieri,

Superior Survival of Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Compared with Chemotherapy Alone Used as Post-Remission Therapy.

Twenty-Year Follow-Up of a Controlled Trial Comparing a Combination of Methotrexate Plus Cyclosporine with Cyclosporine Alone for Prophylaxis of Graft-versus-Host.

Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia–Rearranged Acute Leukemia Who Are at High Risk of.

Allogeneic Peripheral Blood Stem Cell Transplantation is a Promising and Safe Choice for the Treatment of Refractory/Relapsed Acute Myelogenous Leukemia,

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Adults: An Evidence-based.

Mary Eapen Biology of Blood and Marrow Transplantation

Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome–Positive Acute.

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.

Idarubicin-Intensified Hematopoietic Cell Transplantation Improves Relapse and Survival of High-Risk Acute Leukemia Patients with Minimal Residual Disease

Presentation transcript:

Predictors of relapse and overall survival in Philadelphia chromosome–positive acute lymphoblastic leukemia after transplantation Derek L. Stirewalt, Katherine A. Guthrie, Lan Beppu, Eileen M. Bryant, Kris Doney, Ted Gooley, Frederick R. Appelbaum, Jerald P. Radich Biology of Blood and Marrow Transplantation Volume 9, Issue 3, Pages 206-212 (March 2003) DOI: 10.1016/S1083-8791(03)70011-1 Copyright © 2003 American Society for Blood and Marrow Transplantation Terms and Conditions

Fig. 1 OS and DFS estimates for all patients (n = 90). The graph shows that OS and DFS curves essentially overlap one another, indicating that most patients who relapse die. In addition, the curves begin to plateau after 2 years, suggesting that long-term survival is possible. Biology of Blood and Marrow Transplantation 2003 9, 206-212DOI: (10.1016/S1083-8791(03)70011-1) Copyright © 2003 American Society for Blood and Marrow Transplantation Terms and Conditions

Fig. 2 DFS by pretransplantation RT/PCR and disease status. Kaplan-Meier estimates are shown for 3 patient groups: CR and no evidence of bcr-abl expression (CR, bcr-abl −), CR and evidence of bcr-abl expression (CR, bcr-abl +), and relapse. The difference in DFS between patients in CR and relapse was statistically significant (P = .017). The differences between the relapse group and each of the CR groups by bcr-abl expression were not statistically significant, but the groups are shown for descriptive purposes. Biology of Blood and Marrow Transplantation 2003 9, 206-212DOI: (10.1016/S1083-8791(03)70011-1) Copyright © 2003 American Society for Blood and Marrow Transplantation Terms and Conditions

Fig. 3 DFS by RT/PCR from 100 days posttransplantation, stratified by evidence of bcr-abl expression. Risk stratification by expression of bcr-abl within the first 100 days posttransplantation shows a relationship between MRD and DFS (P = .007). Kaplan-Meier estimates are shown for 2 patient groups: no evidence of bcr-abl expression (bcr-abl −) and evidence of bcr-abl expression (bcr-abl +) within the first 100 days posttransplantation. Biology of Blood and Marrow Transplantation 2003 9, 206-212DOI: (10.1016/S1083-8791(03)70011-1) Copyright © 2003 American Society for Blood and Marrow Transplantation Terms and Conditions